Making the US FDA’s “Purple Book” listing of licensed biological products more like its small molecule predecessor, the “Orange Book,” could help promote biosimilar competition, better inform prescribing and dispensing, and boost market uptake, stakeholders told the US FDA at a Sept. 4 hearing.
Listing patent and exclusivity information – as is done in the Orange Book – as well as the date of...






